基于数据挖掘分析VHL，PBRM1，TTN，SETD2，BAP1在肾透明细胞癌中的表达及预后意义
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2019年20期
- 页码:
- 3663-3666
- 栏目:
- 论着（消化·泌尿系肿瘤）
- 出版日期:
- 2019-09-08
文章信息/Info
- Title:
- Expression and prognostic significance of VHL,PBRM1,TTN,SETD2 and BAP1 in renal clear cell carcinoma based on data mining
- Author(s):
- Wang Tao;?Guo Qizhen
- Department of Urology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110004,China.
- Keywords:
- CCRCC;?TCGA database;?Data mining;?TTN;?PBRM1
- 分类号:
- R737.11
- DOI:
- 10.3969/j.issn.1672-4992.2019.20.026
- 文献标识码:
- A
- qq自动领红包软件:
- 目的：研究相关基因在肾透明细胞癌中的表达变化，评价相关基因与肾透明细胞癌的关系及其对预后的影响。方法：在TCGA（The Cancer Genome Atlas）数据库中配对肾透明细胞癌组织和正常肾细胞组织相关基因表达谱数据，通过数据挖掘技术挖掘相关基因（VHL，PBRM1，TTN，SETD2，BAP1）与肾透明细胞癌表达及预后的关系。结果：相对比正常肾透明细胞组织，VHL，PBRM1，SETD2，BAP1均呈低表达，TTN呈高表达，通过建立相关生存曲线，可知PBRM1低表达与TTN高表达能够减少肾透明细胞癌患者的生存时间，而VHL、SETD2、BAP1基因低表达与肾透明细胞癌患者的生存时间无统计学差异。结论：PBRM1的低表达与TTN高表达是影响肾透明细胞癌预后的不良因素，因此PRBM1、TTN基因的表达对判断肾透明细胞癌患者的生存预后具有参考价值。
- Abstract:
- Objective:To study the genes mutation in renal clear cell carcinoma and evaluate the relationship and their effexts between the related genes in renal clear cell carcinoma.Methods:The gene expression profiles of renal clear cell carcinoma tissue and normal renal cell tissue were paired in the TCGA (The Cancer Genome Atlas) database.We chose VHL,PBRM1,TTN,SETD2,BAP1 in clear cell renal cell carcinoma to analysis their relationship with their survival.Results:Compared with normal renal clear cell tissue,VHL,PBRM1,SETD2,and BAP1 showed low expression and TTN was highly expressed.By establishing a survival curve,it can be seen that low expression of PBRM1 and high expression of TTN can reduce the survival of patients with renal clear cell carcinoma.while the low expression of VHL,SETD2,BAP1 gene and their survival time were not statistically different.Conclusion:Low expression of PBRM1 and high expression of TTN are adverse factors affecting the prognosis of renal clear cell carcinoma.Therefore,the expression of PRBM1 and TTN genes haveaimportant role for the prognosis of patients with renal clear cell carcinoma.
参考文献/References
［1］ Siegel R,Naishadham D,Jemal A.Cancer statistics,2012［J］.Ca A Cancer Journal for Clinicians,2010,63(1):11.
［2］CHEN N,ZHOU Q.Progress in pathological diagnosis and research of renal cell carcinoma［J］.Journal of Modern Urology,2016,21(3):164-169.［陈铌,周桥.肾细胞癌的病理诊断与研究进展［J］.现代泌尿外科杂志,2016,21(3):164-169.］
［3］ZHU GD.European Urology:Pyruvate dehydrogenase kinase inhibitor dichloroacetate regulates mitochondrial metabolism and inhibits cancer cell proliferation in clear cell renal cell carcinoma ［J］.Journal of Modern Urology,2016,21(7):557-557.［朱国栋.European Urology:丙酮酸脱氢酶激酶抑制剂二氯醋酸盐调节透明细胞型肾细胞癌线粒体代谢并抑制癌细胞增殖［J］.现代泌尿外科杂志,2016,21(7):557-557.］
［4］XI L,SHEN WS,CAO XM.Changes and correlation of serum tumor markers,HIF-1α and VEGF in patients with non-small cell lung cancer before and after chemotherapy［J］.Journal of Chengdu Medical College,2014,9(2):139 -142.［奚蕾,沈伟生,曹向明.非小细胞肺癌患者化疗前后血清肿瘤标志物、HIF-1α、VEGF的变化及相关性研究［J］.成都医学院学报,2014,9(2):139-142.］
［5］CHEN JD.Research progress in the establishment and application of knockout mouse model of renal cell carcinoma［J］.Journal of Zunyi Medical College,2017,40(4):347-357.［陈金东.肾癌敲基因小鼠模型建立及应用的研究进展［J］.遵义医学院学报,2017,40(4):347-357.］
［6］ Chou A,Fraser S,Toon CW,et al.A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma［J］.American Journal of Surgical Pathology,2015,39(5):652.
［7］ Miao D,Margolis CA,Gao W,et al.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma［J］.Science,2018,8(1):eaan5951.
［8］Espana-Agusti J,Warren A,Chew SK,et al.Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis［J］.Nature Communications,2017,8(1):1-11.
［9］ Savarese M,Maggi L,Vihola A,et al.Interpreting genetic variants in titin in patients with muscle disorders［J］.Jama Neurol,2018,75(5):1-9.
［10］Penallopis S,Christie A,Xie XJ,et al.Cooperation and antagonism among cancer genes:The renal cancer paradigm［J］.Cancer Research,2013,73(14):4173-4179.
［11］Lachner M,O'Sullivan RJ,Jenuwein T.An epigenetic road map for histone lysine methylation［J］.Journal of Cell Science,2003,116(11):2117-2124.
［12］Xie P,Tian C,An L,et al.Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes［J］.Cellular Signalling,2008,20(9):1671-1678.
［13］ Mar BG,Chu SH,Kahn JD,et al.SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia［J］.Blood,2017,8(43):73483-73500.
［14］ Hakimi AA,Ostrovnaya I,Reva B,et al.Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2:a report by MSKCC and the KIRC TCGA research network［J］.Clinical Cancer Research,2013,19(12):3259-3267.
［15］ Nguyen GK,Mellnick VM,Yim AK,et al.Synergy of sex differences in visceral fat measured with CT and tumor metabolism helps predict overall survival in patients with renal cell carcinoma［J］.Radiology,2018,287(3):884-892.
备注/Memo
- 备注/Memo:
- -
